Hospital
John T. Mather Memorial Hospital
John T. Mather Memorial Hospital was paid $20.34M by Medicaid between Jan 2018 and Dec 2024, across 166 billing codes. Its largest line is 90834, psychotherapy session, about 45 minutes — 13% of everything it billed.
33Billing provider infoJOHN T. MATHER MEMORIAL HOSPITAL
PORT JEFFERSON, NY 11777
PORT JEFFERSON, NY 11777
33aNPI1093718728assigned 05/27/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$20.34M
24GClaims396,443
24DCodes billed166
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New York
Rank by total paid#9 of 33
Median peer was paid$171K
This provider vs. median119×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,636 | $190K | |
| 2019 | 25,537 | $1.17M | |
| 2020 | 71,989 | $3.42M | |
| 2021 | 85,613 | $4.39M | |
| 2022 | 84,681 | $4.44M | |
| 2023 | 75,935 | $4.00M | |
| 2024incomplete | 48,052 | $2.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 13% | 15,272 | 7,642 | $2.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 15,401 | 14,158 | $2.52M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 6.8% | 7,760 | 899 | $1.39M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.8% | 7,837 | 7,392 | $1.38M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 5.4% | 11,057 | 3,159 | $1.09M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.4% | 1,021 | 1,013 | $887K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 9,193 | 8,666 | $867K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.9% | 6,246 | 3,688 | $789K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 2,312 | 2,243 | $644K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 2,080 | 2,018 | $598K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.3% | 3,809 | 3,445 | $472K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 2,656 | 2,435 | $471K |
154 more codes
| 36415 | Collection of venous blood by venipuncture | 2.2% | 52,089 | $441K |
| 80053 | Comprehensive metabolic panel | 2.1% | 17,534 | $430K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,837 | $425K |
| 99285 | Emergency room visit (most serious) | 2.1% | 2,855 | $423K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.4% | 2,747 | $286K |
| 90792 | Psychiatric diagnostic evaluation with medical services | 1.3% | 1,436 | $274K |
| 93975 | 1.3% | 387 | $270K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 909 | $247K |
| 90791 | Psychiatric diagnostic evaluation | 1.1% | 1,055 | $224K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 719 | $214K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.0% | 1,209 | $209K |
| 99406 | <1% | 4,309 | $198K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,179 | $192K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,607 | $186K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,298 | $170K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,561 | $129K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 340 | $129K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,339 | $121K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,013 | $113K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,344 | $102K |
| 80061 | Lipid panel | <1% | 7,936 | $98K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,516 | $73K |
| 86850 | <1% | 2,829 | $72K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,670 | $69K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,007 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,963 | $65K |
| 83880 | <1% | 2,060 | $63K | |
| G0378 | Hospital observation service, per hour | <1% | 651 | $56K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,109 | $56K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 609 | $55K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,407 | $52K |
| 86901 | <1% | 2,854 | $51K | |
| 85610 | <1% | 8,574 | $50K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 154 | $50K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 474 | $43K |
| 86900 | <1% | 2,861 | $43K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,280 | $42K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,914 | $36K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 920 | $35K |
| 99442 | <1% | 701 | $34K | |
| 80050 | General health panel | <1% | 896 | $34K |
| 76641 | <1% | 697 | $32K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 360 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,458 | $31K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 829 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,087 | $28K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,890 | $27K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 368 | $25K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,690 | $22K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 131 | $22K |
| 87631 | <1% | 328 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,092 | $19K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 358 | $18K |
| 87486 | <1% | 381 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,005 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 48 | $11K |
| 84439 | <1% | 1,062 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,274 | $11K |
| 82607 | <1% | 767 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 183 | $9K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,794 | $9K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 28 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 454 | $9K |
| 85730 | <1% | 6,839 | $8K | |
| 90715 | <1% | 206 | $8K | |
| 82746 | <1% | 595 | $7K | |
| 93971 | <1% | 70 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,929 | $7K |
| 87581 | <1% | 380 | $7K | |
| 93970 | <1% | 12 | $7K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 31 | $7K |
| 84425 | <1% | 473 | $7K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 38 | $7K |
| 87088 | <1% | 4,132 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,141 | $6K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 55 | $6K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 293 | $6K |
| 83735 | <1% | 6,070 | $6K | |
| 88304 | <1% | 109 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 162 | $5K |
| 99441 | <1% | 199 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 472 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,158 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,582 | $5K |
| 82728 | <1% | 418 | $5K | |
| 81003 | <1% | 11,649 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,619 | $5K |
| 88342 | <1% | 90 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 284 | $4K |
| 84702 | <1% | 2,201 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 27 | $4K |
| 96376 | <1% | 917 | $4K | |
| 81025 | <1% | 1,182 | $4K | |
| 84703 | <1% | 5,847 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $3K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 162 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 122 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,207 | $3K |
| 84484 | <1% | 8,803 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 161 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 550 | $2K |
| J3490 | Unclassified drugs | <1% | 70 | $2K |
| 83550 | <1% | 389 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 244 | $2K |
| 83690 | <1% | 5,567 | $2K | |
| 86617 | <1% | 129 | $2K | |
| 97010 | <1% | 79 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 357 | $1K |
| 80076 | <1% | 121 | $1K | |
| 87070 | <1% | 218 | $1K | |
| 82550 | <1% | 887 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,466 | $1K |
| 87186 | <1% | 697 | $946.39 | |
| 83605 | <1% | 2,270 | $905.09 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $804.23 |
| 84436 | <1% | 147 | $776.68 | |
| 82962 | <1% | 2,027 | $675.65 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 18 | $664.88 |
| 85651 | <1% | 757 | $576.60 | |
| 86666 | <1% | 74 | $557.90 | |
| 82248 | <1% | 142 | $534.13 | |
| 73630 | <1% | 108 | $520.77 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 29 | $518.18 |
| 99408 | <1% | 12 | $518.13 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 63 | $514.11 |
| 84480 | <1% | 92 | $478.26 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25 | $475.21 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 54 | $446.12 |
| 86769 | <1% | 12 | $420.67 | |
| 84100 | <1% | 372 | $416.13 | |
| 84145 | <1% | 1,152 | $412.38 | |
| 84134 | <1% | 57 | $402.38 | |
| 86618 | <1% | 41 | $377.92 | |
| 87040 | <1% | 1,357 | $350.98 | |
| 85379 | <1% | 386 | $337.63 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 455 | $333.46 |
| 86140 | <1% | 169 | $311.96 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 114 | $300.05 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 25 | $263.97 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 417 | $216.83 |
| 82570 | <1% | 24 | $126.36 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 31 | $101.84 |
| 87077 | <1% | 160 | $84.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 72 | $56.89 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 39 | $28.87 |
| 80164 | <1% | 16 | $24.04 | |
| 83615 | <1% | 27 | $16.30 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 14 | $10.80 |
| 86753 | <1% | 13 | $9.76 | |
| 73030 | <1% | 43 | $9.00 | |
| 87205 | <1% | 13 | $8.23 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 54 | $0.00 |
| 73610 | 0% | 18 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (EVP & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.